文献速递消化道肿瘤放疗胸部肿瘤放疗

高剂量对比标准剂量调强放疗联合同期紫杉醇加卡铂治疗胸段食管鳞状细胞癌:一项随机、多中心、开放标签、3期优效性试验

High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-11-17

该随机多中心3期优效性试验纳入167例不可手术胸段食管鳞癌患者,比较59.4 Gy高剂量与50.4 Gy标准剂量调强放疗联合同期紫杉醇加卡铂的疗效。高剂量组与标准剂量组中位总生存分别为28.1个月与26.0个月(P = .54),3级及以上治疗相关毒性分别为62%与68.5%(P = .675)。结论为59.4 Gy高剂量调强放疗对比标准剂量未能改善生存。

要点

  • 高剂量组与标准剂量组中位总生存分别为28.1个月与26.0个月(P = .54),无显著差异。
  • 高剂量组与标准剂量组3级及以上治疗相关毒性分别为62%与68.5%(P = .675)。
  • 共观察到7例治疗相关死亡。

核心结论

  • 对于不可手术的胸段食管鳞状细胞癌患者,采用调强放疗时59.4 Gy剂量对比标准剂量放化疗未能改善生存。

研究设计与样本

  • 随机、多中心、开放标签、3期优效性试验,2016年4月30日至2019年4月30日在中国9个中心入组167例不可手术胸段食管鳞状细胞癌患者,按1:1随机分配至高剂量调强放疗组(59.4 Gy)或标准剂量调强放疗组(50.4 Gy)。
  • 化疗为6周期同期每周紫杉醇加卡铂,最多2周期巩固化疗;对营养筛查提示营养不良的患者实施营养干预;主要终点为中位总生存,采用改良意向性治疗分析。

主要发现

  • 高剂量组71例与标准剂量组73例纳入分析;86.8%的患者完成放疗,70.1%接受5或6周期同期化疗。
  • 中位随访36.0个月,高剂量组与标准剂量组中位总生存分别为28.1个月与26.0个月(P = .54)。
  • 共观察到7例治疗相关死亡;高剂量组与标准剂量组3级及以上治疗相关毒性分别为62%与68.5%(P = .675)。

关键数值与推荐

  • 高剂量调强放疗剂量为59.4 Gy,标准剂量调强放疗剂量为50.4 Gy。
  • 同期化疗为6周期每周紫杉醇加卡铂,巩固化疗最多2周期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The standard dose (SD) of definitive concurrent chemoradiotherapy (dCRT) remains 50.4 Gy in patients with esophageal cancer; a higher dose, when applied with conventional radiation therapy techniques, increases toxicities without improving survival. We investigated whether a high dose of 59.4 Gy using intensity-modulated radiation therapy (IMRT) would improve survival without increasing toxicities. METHODS: Patients with inoperable thoracic esophageal squamous cell carcinoma (SCC) referred for dCRT were randomly assigned (1:1) to high-dose (HD) IMRT (59.4 Gy) or SD IMRT (50.4 Gy). Chemotherapy consisted of 6 cycles of concurrent weekly paclitaxel and carboplatin and a maximum of 2 cycles of consolidation chemotherapy. Nutritional intervention was implemented for patients with malnutrition on the basis of nutritional screening. The primary endpoint was median overall survival (mOS). Analyses were by modified intention to treat. RESULTS: Between April 30, 2016, and April 30, 2019, 167 patients were enrolled at 9 participating centers in China. Seventy-one patients in the HD and 73 patients in the SD groups were included in the analysis; 86.8% of the patients completed radiation therapy and 70.1% received 5 or 6 cycles of concurrent chemotherapy. The median follow-up was 36.0 months. The mOS was 28.1 and 26.0 months in the HD and SD arms, respectively (P = .54). A total of 7 treatment-related deaths were observed. Grade 3 or worse treatment-related toxicities were observed in 62% and 68.5% of the patients in the HD and SD arms, respectively (P = .675). CONCLUSIONS: For patients with inoperable thoracic esophageal SCC, a dose of 59.4 Gy did not improve survival compared with the SD of dCRT using IMRT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. You J, Zhu S, Li J, et al. High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 36402359. doi:10.1016/j.ijrobp.2022.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。